Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school

BMC Cancer

Research Article

Fernanda Maris Peria¹  Leonardo Régis Leira Pereira²  Altacílio Aparecido Nunes³  Andrea Queiróz Ungari⁴ 

[1] Clinical Oncology Division - Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil;Department of Pharmaceutical Sciences, School of Pharmaceutical Sciences, University of São Paulo, Ribeirão Preto, Brazil;Department of Social Medicine, Ribeirão Preto Medical School, University of São Paulo, São Paulo, Brazil;Division of Pharmaceutical Assistance, General Hospital of Ribeirão Preto Medical School, University of São Paulo, Campus Universitário, s/n - Vila Monte Alegre, 14049-900, Ribeirão Preto, SP, Brazil;

关键词: Colorectal Neoplasms;    Cost-effectiveness evaluation;    Bevacizumab;    Unified health system;    Brazil;   

DOI  :  10.1186/s12885-017-3679-5

 received in 2017-06-18, accepted in 2017-10-09,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundMetastatic colorectal cancer imposes a substantial burden on patients and society. Over the last years, progresses in the treatment have been made especially due to the introduction of monoclonal antibodies, such as bevacizumab which, on the other hand, has considerably increased the costs of treatment. We performed a cost-effectiveness analysis of bevacizumab plus XELOX in comparison with XELOX alone in metastatic colorectal cancer in first-line therapy, from the perspective of a public hospital school in Brazil.MethodsThis was a cost-effectiveness analysis performed by a decision tree and Markov models. Costs were expressed in local currency and outcomes were expressed in months of life gained. The model was constructed using the TreeAge Pro 2013® software.ResultsThe incremental difference in years of life gained was 2.25 months, with an extra cost of 47,833.57 BRL, resulting in an incremental cost-effectiveness of 21,231.43 BRL per month of life gained.ConclusionsAlthough the XELOX plus bevacizumab regimen is a more expensive and more effective treatment than XELOX, it does not fit the reimbursement values fixed by the public healthcare system in Brazil.

【 授权许可】

CC BY   
© The Author(s). 2017